|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DHODH |
Gene summary for DHODH |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DHODH | Gene ID | 1723 |
| Gene name | dihydroorotate dehydrogenase (quinone) | |
| Gene Alias | DHOdehase | |
| Cytomap | 16q22.2 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q02127 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1723 | DHODH | S43 | Human | Liver | Cirrhotic | 6.09e-04 | -9.49e-02 | -0.0187 |
| 1723 | DHODH | HCC1_Meng | Human | Liver | HCC | 6.76e-34 | -8.84e-02 | 0.0246 |
| 1723 | DHODH | HCC2_Meng | Human | Liver | HCC | 1.85e-03 | -1.29e-01 | 0.0107 |
| 1723 | DHODH | HCC1 | Human | Liver | HCC | 3.03e-02 | 2.05e+00 | 0.5336 |
| 1723 | DHODH | HCC2 | Human | Liver | HCC | 8.48e-04 | 1.29e+00 | 0.5341 |
| 1723 | DHODH | S029 | Human | Liver | HCC | 9.92e-06 | 4.65e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:000675312 | Liver | Cirrhotic | nucleoside phosphate metabolic process | 190/4634 | 497/18723 | 1.10e-11 | 6.96e-10 | 190 |
| GO:000911712 | Liver | Cirrhotic | nucleotide metabolic process | 187/4634 | 489/18723 | 1.55e-11 | 9.63e-10 | 187 |
| GO:001969312 | Liver | Cirrhotic | ribose phosphate metabolic process | 156/4634 | 396/18723 | 5.83e-11 | 3.23e-09 | 156 |
| GO:000925912 | Liver | Cirrhotic | ribonucleotide metabolic process | 151/4634 | 385/18723 | 1.72e-10 | 8.70e-09 | 151 |
| GO:004259412 | Liver | Cirrhotic | response to starvation | 87/4634 | 197/18723 | 1.85e-09 | 7.78e-08 | 87 |
| GO:003166712 | Liver | Cirrhotic | response to nutrient levels | 174/4634 | 474/18723 | 3.08e-09 | 1.27e-07 | 174 |
| GO:000941012 | Liver | Cirrhotic | response to xenobiotic stimulus | 165/4634 | 462/18723 | 6.82e-08 | 2.09e-06 | 165 |
| GO:004873212 | Liver | Cirrhotic | gland development | 154/4634 | 436/18723 | 4.03e-07 | 9.42e-06 | 154 |
| GO:00108216 | Liver | Cirrhotic | regulation of mitochondrion organization | 62/4634 | 144/18723 | 1.09e-06 | 2.22e-05 | 62 |
| GO:00091232 | Liver | Cirrhotic | nucleoside monophosphate metabolic process | 36/4634 | 76/18723 | 1.55e-05 | 2.11e-04 | 36 |
| GO:00091121 | Liver | Cirrhotic | nucleobase metabolic process | 20/4634 | 34/18723 | 2.41e-05 | 3.14e-04 | 20 |
| GO:000916111 | Liver | Cirrhotic | ribonucleoside monophosphate metabolic process | 29/4634 | 58/18723 | 2.87e-05 | 3.64e-04 | 29 |
| GO:00463905 | Liver | Cirrhotic | ribose phosphate biosynthetic process | 71/4634 | 190/18723 | 7.09e-05 | 7.98e-04 | 71 |
| GO:00092605 | Liver | Cirrhotic | ribonucleotide biosynthetic process | 68/4634 | 182/18723 | 1.00e-04 | 1.05e-03 | 68 |
| GO:00091654 | Liver | Cirrhotic | nucleotide biosynthetic process | 89/4634 | 254/18723 | 1.45e-04 | 1.40e-03 | 89 |
| GO:19012934 | Liver | Cirrhotic | nucleoside phosphate biosynthetic process | 89/4634 | 256/18723 | 1.97e-04 | 1.82e-03 | 89 |
| GO:00062061 | Liver | Cirrhotic | pyrimidine nucleobase metabolic process | 11/4634 | 16/18723 | 2.58e-04 | 2.30e-03 | 11 |
| GO:00011013 | Liver | Cirrhotic | response to acid chemical | 52/4634 | 135/18723 | 2.65e-04 | 2.36e-03 | 52 |
| GO:0006220 | Liver | Cirrhotic | pyrimidine nucleotide metabolic process | 24/4634 | 50/18723 | 3.06e-04 | 2.68e-03 | 24 |
| GO:00432002 | Liver | Cirrhotic | response to amino acid | 45/4634 | 116/18723 | 5.54e-04 | 4.36e-03 | 45 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa01240 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
| hsa00240 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa012401 | Liver | Cirrhotic | Biosynthesis of cofactors | 66/2530 | 153/8465 | 3.11e-04 | 1.99e-03 | 1.23e-03 | 66 |
| hsa002401 | Liver | Cirrhotic | Pyrimidine metabolism | 27/2530 | 58/8465 | 5.31e-03 | 1.88e-02 | 1.16e-02 | 27 |
| hsa012402 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa002402 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| hsa012403 | Liver | HCC | Biosynthesis of cofactors | 103/4020 | 153/8465 | 4.67e-07 | 5.05e-06 | 2.81e-06 | 103 |
| hsa002403 | Liver | HCC | Pyrimidine metabolism | 44/4020 | 58/8465 | 9.34e-06 | 7.11e-05 | 3.95e-05 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DHODH | SNV | Missense_Mutation | novel | c.323N>C | p.Tyr108Ser | p.Y108S | Q02127 | protein_coding | tolerated(0.27) | benign(0.001) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
| DHODH | SNV | Missense_Mutation | novel | c.53N>A | p.Gly18Glu | p.G18E | Q02127 | protein_coding | deleterious(0.03) | possibly_damaging(0.729) | TCGA-E2-A15S-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
| DHODH | insertion | Frame_Shift_Ins | novel | c.1126_1127insCTCCGGGATTTATCAACTCAAACCA | p.Leu376ProfsTer54 | p.L376Pfs*54 | Q02127 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| DHODH | insertion | Nonsense_Mutation | novel | c.325_326insGGGCCTGACACCAGCGAGCTACTCCCTCCCACCAAGGCT | p.Lys109delinsArgAlaTerHisGlnArgAlaThrProSerHisGlnGlyTer | p.K109delinsRA*HQRATPSHQG* | Q02127 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| DHODH | SNV | Missense_Mutation | novel | c.514N>A | p.Glu172Lys | p.E172K | Q02127 | protein_coding | tolerated(0.68) | benign(0.001) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| DHODH | SNV | Missense_Mutation | c.404N>A | p.Arg135His | p.R135H | Q02127 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| DHODH | SNV | Missense_Mutation | rs267606768 | c.730N>T | p.Arg244Trp | p.R244W | Q02127 | protein_coding | deleterious(0.04) | possibly_damaging(0.673) | TCGA-AA-3660-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DHODH | SNV | Missense_Mutation | rs776827112 | c.206G>A | p.Arg69Gln | p.R69Q | Q02127 | protein_coding | tolerated(0.12) | benign(0.013) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DHODH | SNV | Missense_Mutation | c.50N>C | p.Leu17Pro | p.L17P | Q02127 | protein_coding | deleterious(0.03) | possibly_damaging(0.781) | TCGA-AA-3811-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
| DHODH | SNV | Missense_Mutation | c.190N>A | p.Leu64Met | p.L64M | Q02127 | protein_coding | tolerated(0.18) | benign(0.018) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | LEFLUNOMIDE | LEFLUNOMIDE | ||
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | inhibitor | 375973210 | ||
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | LEFLUNOMIDE | LEFLUNOMIDE | ||
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL973 | TERIFLUNOMIDE | |
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | leflunomide | LEFLUNOMIDE | 19207032 | |
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL960 | LEFLUNOMIDE | |
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | IMMUNOSUPPRESSIVE | 7575649 | ||
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | LAS-186323 | |||
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | LEFLUNOMIDE | LEFLUNOMIDE | ||
| 1723 | DHODH | DRUGGABLE GENOME, ENZYME | BAY2402234 |
| Page: 1 2 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |